Tome Biosciences

Executive Summary

Tome Biosciences is a preclinical-stage gene editing company developing a novel platform for programmable genomic integration, enabling precise insertion of large DNA sequences at any genomic location. Its technology, based on PASTE (Programmable Addition via Site-specific Targeting Elements), overcomes key limitations of traditional CRISPR-Cas9, such as off-target effects and inability to integrate large genetic payloads. Tome is targeting both ex-vivo cell therapies (e.g., CAR-T for oncology) and in-vivo genetic medicines (e.g., for genetic diseases). The company was founded in 2021 and has raised $213 million, reflecting strong investor confidence in its platform. With a robust preclinical pipeline and a clear therapeutic focus, Tome is positioned to become a leader in next-generation gene editing. However, the company has yet to enter clinical trials, and its valuation remains modest given the early stage.

Upcoming Catalysts (preview)

• Q3 2026IND Filing for Lead In-Vivo Program (e.g., Metabolic Genetic Disease)65% success
• Q3 2026Preclinical Data Presentation at Major Gene Therapy Conference (e.g., ESGCT or ASGCT)80% success
• TBDStrategic Partnership or Licensing Deal for Ex-Vivo Cell Therapy Platform55% success